FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337908372> ?p ?o ?g. }

• W2337908372 endingPage "762" @default.
• W2337908372 startingPage "755" @default.
• W2337908372 abstract "About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction‐consolidation program between 2004 and 2013 were retrospectively analyzed. Median age was 47 years. The first induction course included fludarabine (Flu) and high‐dose cytarabine (Ara‐C) plus idarubicin (Ida), with or without gemtuzumab‐ozogamicin (GO) 3 mg/m 2 (FLAI‐5). Patients achieving complete remission (CR) received a second course without fludarabine but with higher dose of idarubicin. Patients not achieving CR received an intensified second course. Patients not scheduled for early allogeneic bone marrow transplantation (HSCT) where planned to receive at least two courses of consolidation therapy with Ara‐C. Our double induction strategy significantly differs from described fludarabine‐containing regimens, as patients achieving CR receive a second course without fludarabine, to avoid excess toxicity, and Ara‐C consolidation is administrated at the reduced cumulative dose of 8 g/m 2 per cycle. Toxicity is a major concern in fludarabine containing induction, including the recent Medical Research Council AML15 fludarabine, cytarabine, idaraubicin and G‐CSF (FLAG‐Ida) arm, and, despite higher anti‐leukemic efficacy, only a minority of patients is able to complete the full planned program. In this article, we show that our therapeutic program is generally well tolerated, as most patients were able to receive subsequent therapy at full dose and in a timely manner, with a 30‐day mortality of 4.8%. The omission of fludarabine in the second course did not reduce efficacy, as a CR rate of 83% was achieved and 3‐year disease‐free survival and overall survival (OS) were 49.6% and 50.9%, respectively. Our experience shows that FLAI‐5/Ara‐C + Ida double induction followed by risk‐oriented consolidation therapy can result in good overall outcome with acceptable toxicity. Am. J. Hematol. 91:755–762, 2016. © 2016 Wiley Periodicals, Inc." @default.
• W2337908372 created "2016-06-24" @default.
• W2337908372 creator A5003135516 @default.
• W2337908372 creator A5006684853 @default.
• W2337908372 creator A5007754732 @default.
• W2337908372 creator A5009267255 @default.
• W2337908372 creator A5015539158 @default.
• W2337908372 creator A5024003266 @default.
• W2337908372 creator A5030838026 @default.
• W2337908372 creator A5033482554 @default.
• W2337908372 creator A5039803007 @default.
• W2337908372 creator A5048224601 @default.
• W2337908372 creator A5061850537 @default.
• W2337908372 creator A5066888430 @default.
• W2337908372 creator A5068220742 @default.
• W2337908372 creator A5068251696 @default.
• W2337908372 creator A5078922292 @default.
• W2337908372 creator A5084040459 @default.
• W2337908372 date "2016-06-15" @default.
• W2337908372 modified "2023-09-27" @default.
• W2337908372 title "High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients" @default.
• W2337908372 cites W1255676896 @default.
• W2337908372 cites W1534965621 @default.
• W2337908372 cites W1536174937 @default.
• W2337908372 cites W1819781110 @default.
• W2337908372 cites W1965784693 @default.
• W2337908372 cites W1972290531 @default.
• W2337908372 cites W1972988368 @default.
• W2337908372 cites W1977917277 @default.
• W2337908372 cites W1995090169 @default.
• W2337908372 cites W1996815004 @default.
• W2337908372 cites W2010732369 @default.
• W2337908372 cites W2012469472 @default.
• W2337908372 cites W2025013227 @default.
• W2337908372 cites W2025086811 @default.
• W2337908372 cites W2034820298 @default.
• W2337908372 cites W2043216151 @default.
• W2337908372 cites W2044088883 @default.
• W2337908372 cites W2068709179 @default.
• W2337908372 cites W2073196300 @default.
• W2337908372 cites W2073866744 @default.
• W2337908372 cites W2089596135 @default.
• W2337908372 cites W2089899349 @default.
• W2337908372 cites W2099972381 @default.
• W2337908372 cites W2114441791 @default.
• W2337908372 cites W2116858301 @default.
• W2337908372 cites W2136628941 @default.
• W2337908372 cites W2138265677 @default.
• W2337908372 cites W2139717439 @default.
• W2337908372 cites W2144395887 @default.
• W2337908372 cites W2146862320 @default.
• W2337908372 cites W2148883973 @default.
• W2337908372 cites W2153310476 @default.
• W2337908372 cites W2153994826 @default.
• W2337908372 cites W2156861341 @default.
• W2337908372 cites W2158022600 @default.
• W2337908372 cites W2159170728 @default.
• W2337908372 cites W2324143682 @default.
• W2337908372 cites W2497311781 @default.
• W2337908372 cites W4231346141 @default.
• W2337908372 doi "https://doi.org/10.1002/ajh.24391" @default.
• W2337908372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27084986" @default.
• W2337908372 hasPublicationYear "2016" @default.
• W2337908372 type Work @default.
• W2337908372 sameAs 2337908372 @default.
• W2337908372 citedByCount "16" @default.
• W2337908372 countsByYear W23379083722017 @default.
• W2337908372 countsByYear W23379083722018 @default.
• W2337908372 countsByYear W23379083722019 @default.
• W2337908372 countsByYear W23379083722020 @default.
• W2337908372 countsByYear W23379083722021 @default.
• W2337908372 crossrefType "journal-article" @default.
• W2337908372 hasAuthorship W2337908372A5003135516 @default.
• W2337908372 hasAuthorship W2337908372A5006684853 @default.
• W2337908372 hasAuthorship W2337908372A5007754732 @default.
• W2337908372 hasAuthorship W2337908372A5009267255 @default.
• W2337908372 hasAuthorship W2337908372A5015539158 @default.
• W2337908372 hasAuthorship W2337908372A5024003266 @default.
• W2337908372 hasAuthorship W2337908372A5030838026 @default.
• W2337908372 hasAuthorship W2337908372A5033482554 @default.
• W2337908372 hasAuthorship W2337908372A5039803007 @default.
• W2337908372 hasAuthorship W2337908372A5048224601 @default.
• W2337908372 hasAuthorship W2337908372A5061850537 @default.
• W2337908372 hasAuthorship W2337908372A5066888430 @default.
• W2337908372 hasAuthorship W2337908372A5068220742 @default.
• W2337908372 hasAuthorship W2337908372A5068251696 @default.
• W2337908372 hasAuthorship W2337908372A5078922292 @default.
• W2337908372 hasAuthorship W2337908372A5084040459 @default.
• W2337908372 hasBestOaLocation W23379083722 @default.
• W2337908372 hasConcept C10205521 @default.
• W2337908372 hasConcept C126322002 @default.
• W2337908372 hasConcept C141071460 @default.
• W2337908372 hasConcept C143998085 @default.
• W2337908372 hasConcept C176290653 @default.
• W2337908372 hasConcept C2776694085 @default.
• W2337908372 hasConcept C2776755627 @default.
• W2337908372 hasConcept C2778041864 @default.
• W2337908372 hasConcept C2778623314 @default.

• next